Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors
July 27 2022 - 4:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases such as non-alcoholic steatohepatitis (NASH), obesity and
cancer, today announced the appointment of Radhika Tripuraneni,
M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni
serves as the Chief Development Officer of Prothena Corporation plc
and brings to the Terns Board of Directors more than 15 years of
experience in drug development.
“Terns’ approach of discovering and developing next-generation
small molecules for clinically de-risked targets in indications
with significant unmet need is an exciting strategy,” said Dr.
Tripuraneni. “I am thrilled to join this accomplished team and look
forward to working with the board and the management team to
advance three clinically validated mechanisms in three indications
with large, unmet needs towards three important clinical readouts
across NASH, oncology and obesity.”
“Dr. Tripuraneni has a breadth of scientific, medical and drug
development expertise and I am pleased to have her join our board
of directors where she will provide valuable support to our
mission,” said Sen Sundaram, Chief Executive Officer of Terns. “Her
strategic and operational experience in bringing important
treatments to patients positions her well to guide Terns towards
generating meaningful clinical data across several indications in
the coming years.”
Dr. Tripuraneni has served as Prothena’s Chief Development
Officer since 2018 and is a seasoned biotech executive. Prior to
joining Prothena, Dr. Tripuraneni was Vice President, Medical
Affairs and Chief of Staff to the Chief Medical Officer of
MyoKardia Inc. She was Vice President, Medical Affairs at Synageva
BioPharma Corp. and then Alexion Pharmaceuticals Inc., which
acquired Synageva. Earlier in her career, Dr. Tripuraneni held
various medical director and business development positions at
Gilead Sciences, Inc. and Genzyme Corporation, and worked at Summer
Street Research Partners, a healthcare equity research firm.
Dr. Tripuraneni earned her Bachelor’s degrees in business
administration and liberal arts and her M.D. from the University of
Missouri, and her Master’s in Public Health from Harvard
University. She did her clinical training in general surgery at
Harvard - Beth Israel Deaconess Medical Center.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases such as NASH, obesity and cancer. Terns’
pipeline includes four clinical stage development programs
including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR
agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1
receptor agonist program. For more information, please visit:
www.ternspharma.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements about
Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”)
within the meaning of the federal securities laws, including those
related to the Company’s expectations of timing and potential
results of the Company’s clinical trials and other development
activities; the potential indications to be targeted by the Company
with its single-agent and combination therapy candidates; the
therapeutic potential of the Company’s single-agent and combination
therapy candidates; the potential for the mechanisms of action of
the Company’s product candidates to be therapeutic targets for
their targeted indications; the potential utility and progress of
the Company’s product candidates in their targeted indications,
including the clinical utility of the data from and the endpoints
used in the Company’s clinical trials; the Company’s clinical
development plans and activities; the Company’s expectations
regarding the profile of its product candidates, including
tolerability, safety, metabolic stability and pharmacokinetic
profile and potential differentiation as compared to other products
or product candidates; and the Company’s plans for and ability to
continue to execute on its current clinical strategy. All
statements other than statements of historical facts contained in
this press release, including statements regarding the Company’s
strategy, future financial condition, future operations, future
trial results, projected costs, prospects, plans, objectives of
management and expected market growth, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results and the implementation of the Company’s plans to
vary materially, including the risks associated with the
initiation, cost, timing, progress, results and utility of the
Company’s current and future research and development activities
and preclinical studies and clinical trials. In particular, the
impact of the COVID-19 pandemic on the Company’s ability to
progress with its research, development, manufacturing and
regulatory efforts, including the Company’s clinical trials for its
product candidates, will depend on future developments that are
highly uncertain and cannot be predicted with confidence at this
time, such as the ultimate duration of the pandemic, travel
restrictions, quarantines, social distancing and business closure
requirements in the United States and in other countries, and the
effectiveness of actions taken globally to contain and treat the
disease. These risks are not exhaustive. For a detailed discussion
of the risk factors that could affect the Company’s actual results,
please refer to the risk factors identified in the Company’s SEC
reports, including but not limited to its Annual Report on Form
10-K for the year ended December 31, 2021 and its Quarterly Report
on Form 10-Q for the period ended March 31, 2022. Except as
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2023 to Apr 2024